中药单体干预增生性玻璃体视网膜病变的研究进展
Research Progress on the Intervention of Chinese Medicine Monomers in Proliferative Vitreoretinopathy
赵敏瑶 1虞玥 1宋正宇1
作者信息
- 1. 上海中医药大学附属曙光医院,上海 201203
- 折叠
摘要
增生性玻璃体视网膜病变(PVR)是导致孔源性视网膜脱离手术失败和复发的主要原因.目前临床治疗PVR多以手术为主,但存在一定不足,因此,需要寻找新的药物疗法.中药单体兼有中药与化学药的双重优势,我国传统中药与中药单体在PVR治疗尤其是视网膜保护方面具有独特优势,逐渐成为了研究热点.本文对近年来中药单体治疗PVR的文献进行综述,发现姜黄素、藏红花素、槲皮素等中药单体可通过降低血小板源性生长因子、转化生长因子、表皮生长因子等因子的表达,抑制上皮细胞—间充质转化的生物学过程,防止PVR的发生.这些中药单体的发现对后续新药的研发可提供新的选择,为PVR的治疗提供更多元化的方法.
Abstract
Proliferative vitreoretinopathy(PVR)is a major cause of surgical failure and recur-rence in rhegmatogenous retinal detachment.Current clinical treatments for PVR mainly rely on surgery,but they have certain limitations.Therefore,it is necessary to explore new medicine thera-pies.Chinese medicine monomers,with the dual advantages of Chinese medicine and chemical medicines,have become a research focus,particularly in the protection of the retina in PVR treat-ment.This article reviews the literature on the treatment of PVR with Chinese medicine monomers in recent years.It was found that monomers such as curcumin,saffron,and quercetin can lower the expression of platelet-derived growth factor,transforming growth factor,epidermal growth factor,and other factors.They inhibit the biological process of epithelial-mesenchymal transition,prevent-ing the occurrence of PVR.The discovery of these Chinese medicine monomers provides new op-tions for the development of novel medicines and offers a more diversified approach to the treat-ment of PVR.
关键词
增生性玻璃体视网膜病变/中药单体/视网膜色素上皮细胞/病理机制Key words
proliferative vitreoretinopathy/Chinese medicine monomers/retinal pigment epi-thelial cells/pathological mechanism引用本文复制引用
基金项目
上海市自然科学基金(18ZR1440200)
上海中医药大学附属曙光医院四明青年基金(SGKJ-202111)
出版年
2024
国家科技期刊平台
NSTL
维普
万方数据